Comparative Pharmacology
Head-to-head clinical analysis: ONGENTYS versus TOLCAPONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ONGENTYS versus TOLCAPONE.
ONGENTYS vs TOLCAPONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ongentys (opicapone) is a selective and reversible inhibitor of catechol-O-methyltransferase (COMT). By inhibiting COMT, it decreases the metabolism of levodopa to 3-O-methyldopa, thereby increasing plasma levodopa levels and enhancing its bioavailability in the brain, leading to improved dopaminergic effects.
Tolcapone is a selective and reversible inhibitor of catechol-O-methyltransferase (COMT). It inhibits both peripheral and central COMT activity, thereby reducing the metabolism of levodopa to 3-O-methyldopa and increasing the bioavailability and duration of action of levodopa in the brain.
50 mg orally once daily, taken at bedtime.
100 mg orally three times daily. The first dose of the day should be taken together with the first daily dose of levodopa/carbidopa.
None Documented
None Documented
Clinical Note
moderateTolcapone + Torasemide
"The risk or severity of adverse effects can be increased when Tolcapone is combined with Torasemide."
Clinical Note
moderateTolcapone + Etacrynic acid
"The risk or severity of adverse effects can be increased when Tolcapone is combined with Etacrynic acid."
Clinical Note
moderateTolcapone + Furosemide
"The risk or severity of adverse effects can be increased when Tolcapone is combined with Furosemide."
Clinical Note
moderateTolcapone + Bumetanide
The terminal elimination half-life of opicapone is approximately 1 to 2 hours at low doses, but at therapeutic doses (50 mg) it exhibits nonlinear pharmacokinetics with an effective half-life of about 12 to 16 hours due to tight binding to COMT enzyme, allowing once-daily dosing.
Terminal elimination half-life is 2–3 hours in healthy subjects; in patients with hepatic impairment, it may be prolonged up to 8–10 hours, necessitating dose reduction.
Following oral administration, approximately 30% of the dose is excreted in urine as unchanged opicapone, with an additional 10% as glucuronide conjugates. The remainder is eliminated via biliary/fecal routes, accounting for about 60% of the dose.
Primarily hepatic metabolism (glucuronidation and methylation), with minimal renal excretion of unchanged drug. Fecal excretion accounts for approximately 40% of the dose, with 14% excreted in urine as glucuronide conjugates. Less than 1% of the dose is recovered as unchanged tolcapone in urine.
Category C
Category A/B
COMT Inhibitor
COMT Inhibitor
"The risk or severity of adverse effects can be increased when Tolcapone is combined with Bumetanide."